6月5日 - ** 医疗设备制造商BioCardia（BCDA.O）的股价在盘前交易中上涨18%，至1.08美元
** BCDA 表示 (link) 美国食品药品监督管理局已确认，该公司正在进行的心力衰竭疗法晚期临床研究，有望为未来的上市申请提供支持
** 该实验性疗法CardiAMP细胞治疗系统目前正用于泵血功能减退的缺血性心力衰竭患者
** CardiAMP利用患者自身的骨髓细胞，通过微创导管手术将其输送至心脏
** 该疗法已获得FDA突破性疗法认定，该资格旨在加速开发那些可能在现有治疗方案基础上带来显著改善的产品
** 截至上一交易日收盘，BCDA股价年内累计下跌约27%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.